SCHEMBL2901490

SCHEMBL2901490

COc1ccc(F)cc1CNc1ccc2c(OCc3ccccc3)cccc2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.49
LMNA P02545 6/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PDGFRB P09619 1/20 0.45
PDGFRA P16234 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 2/20 0.43
NPY1R P25929 1/20 0.43
HTT P42858 1/20 0.43
NPY2R P49146 1/20 0.43
KMT2A Q03164 1/20 0.43
CYP1A2 P05177 5/20 0.43
CYP3A4 P08684 5/20 0.43
CYP2D6 P10635 5/20 0.43
CYP2C19 P33261 5/20 0.43
TSHR P16473 4/20 0.43
ALOX15 P16050 3/20 0.43
USP2 O75604 3/20 0.43
HSD17B10 Q99714 1/20 0.43
NCF1 P14598 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2250947 0.91 PLA2G1B (0.51) PKMLMNAL3MBTL1SMN1; SMN2KDM4E
SCHEMBL2909572 0.90 CYP1A2 (0.50) LMNAL3MBTL1PDGFRBPDGFRASMN1; SMN2
SCHEMBL2908770 0.84 LMNA (0.55) LMNASMN1; SMN2KDM4EHTTKMT2A
SCHEMBL2902087 0.82 CYP1A2 (0.55) LMNAKDM4EKMT2ACYP1A2CYP3A4
SCHEMBL2909429 0.81 CYP1A2 (0.49) LMNASMN1; SMN2KDM4EKMT2ACYP1A2
SCHEMBL2250949 0.80 MAOB (0.47) LMNASMN1; SMN2KDM4EHTTKMT2A
SCHEMBL2253396 0.79 CYP1A2 (0.55) LMNASMN1; SMN2KDM4EKMT2ACYP1A2
SCHEMBL2907740 0.78 CYP1A2 (0.52) LMNAL3MBTL1SMN1; SMN2KDM4EKMT2A
SCHEMBL2250681 0.77 NCF1 (0.55) LMNAKMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL2907752 0.77 CYP1A2 (0.54) LMNASMN1; SMN2KDM4EKMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825253-B2 2-aminoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2010-11-02 US disclosed
EP-2076495-B1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES HOFFMANN LA ROCHE (CH) 2010-08-18 EP disclosed
EP-2076495-A1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES F.HOFFMANN-LA ROCHE AG (CH) 2009-07-08 EP disclosed
WO-2008037626-A1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES F. HOFFMANN-LA ROCHE AG (CH) 2008-04-03 WO disclosed
US-20080081907-A1 2-AMINOQUINOLINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081907-A1 2-AMINOQUINOLINE DERIVATIVES AR, ADRA2C, RCC2 PKM 2851/4885LMNA 2311/4885L3MBTL1 3963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.